# Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride

> **NCT01233622** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 317 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Vildagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01233622
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01233622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01233622, "Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01233622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*